SCHEMBL23923926

SCHEMBL23923926

Oc1cccc(O)c1-c1ccn[nH]1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.64
SCN4A P35499 1/20 0.48
PIM1 P11309 1/20 0.47
HPGDS O60760 1/20 0.44
NOTUM Q6P988 3/20 0.44
PDPK1 O15530 1/20 0.43
APP P05067 2/20 0.43
CD74 P04233 1/20 0.43
MIF P14174 1/20 0.43
POLB P06746 2/20 0.42
CYP2E1 P05181 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP2B6 P20813 1/20 0.42
AURKA O14965 1/20 0.42
CDK1 P06493 1/20 0.42
CDK2 P24941 1/20 0.42
AURKB Q96GD4 1/20 0.42
MDM2 Q00987 1/20 0.41
PTPN11 Q06124 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536764 0.82 IDO1 (0.50) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL1501845 0.78 IDO1 (1.00) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL29998937 0.78 IDO1 (1.00) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL27917554 0.77 IDO1 (0.96) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL30763901 0.76 IDO1 (0.51) IDO1SCN4APIM1POLBAURKA
SCHEMBL27994186 0.74 NOTUM (0.50) IDO1SCN4AHPGDSNOTUMPDPK1
SCHEMBL3068150 0.72 SCN4A (0.62) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL30837200 0.71 IDO1 (0.64) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL5536772 0.71 IDO1 (0.64) IDO1SCN4APIM1HPGDSNOTUM
SCHEMBL23923840 0.69 PTGS2 (0.46) CYP2A6CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3901142-A1 PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2021-10-27 EP disclosed
US-20210323927-A1 PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323927-A1 PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 GPR18, TRPV1, TRPV3 IDO1 2127/4885SCN4A 898/4885PIM1 4119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.